Exemestane (Aromasin)
Educational information only — not medical advice. Many listed compounds are not FDA-approved for human use. Consult a licensed clinician before starting, changing, or stopping any protocol.
Overview
Exemestane is a steroidal aromatase inhibitor best known by the brand name Aromasin. It is FDA-approved for the treatment of estrogen-receptor-positive breast cancer in postmenopausal women, where lowering circulating estrogen is the therapeutic goal.
Structurally it is a derivative of androstenedione, which lets it slot into the aromatase enzyme as a false substrate. Unlike the non-steroidal inhibitors anastrozole and letrozole, exemestane binds aromatase irreversibly — the basis for its “suicide inhibitor” nickname.
Outside of its approved oncology indication, exemestane is sometimes discussed by people on testosterone replacement therapy or anabolic protocols as a way to manage elevated estradiol. These uses are off-label and are not an approved indication.
How it works
Aromatase is the enzyme that converts androgens such as testosterone and androstenedione into estrogens. Exemestane is processed by aromatase into a reactive intermediate that binds covalently to the enzyme’s active site, permanently inactivating that enzyme molecule. Because the enzyme must be newly synthesized to restore activity, the effect is longer-lasting than that of reversible, competitive inhibitors.
In studies of postmenopausal women, exemestane produced substantial suppression of circulating estrone and estradiol. This irreversible mechanism is the commonly cited reason it is reported not to cause the estrogen rebound sometimes observed after discontinuing a reversible inhibitor.
Reported benefits
- Studied and approved for lowering estrogen in postmenopausal breast cancer
- Reported to reduce elevated estradiol when used off-label alongside TRT or anabolic protocols
- Commonly reported not to produce the estrogen rebound associated with stopping some non-steroidal inhibitors
- Selective for aromatase, with minimal reported interference with adrenal steroid synthesis in study settings
These are reported and studied effects, not guaranteed outcomes, and its estrogen-management use is off-label.
Considerations & side effects
Aggressively lowering estrogen can cause its own problems, including joint aches, low libido, mood changes, fatigue, and unfavorable shifts in cholesterol. Estrogen also plays a role in bone health, and clinical studies of exemestane documented reductions in bone mineral density over time, which is why bone health is a commonly monitored consideration during extended use.
Because estrogen needs differ from person to person, off-label estrogen management is highly individual and easy to overshoot. Exemestane is a prescription medication and is not a substitute for evaluation, lab monitoring, and treatment by a qualified clinician.
Frequently asked
What is exemestane?
Exemestane is a steroidal, irreversible ('suicide') aromatase inhibitor. It lowers estrogen by permanently binding and inactivating the aromatase enzyme, which converts androgens into estrogens.
Is exemestane FDA-approved?
Yes. Exemestane (brand name Aromasin) is FDA-approved for treating certain postmenopausal breast cancers. Its use to manage estrogen on TRT or anabolic-steroid protocols is off-label and not an approved indication.
How is exemestane different from anastrozole?
Anastrozole is a non-steroidal, reversible aromatase inhibitor, while exemestane is steroidal and binds aromatase irreversibly. Because exemestane inactivates the enzyme rather than competing with it, it is commonly reported not to produce the estrogen rebound sometimes seen when anastrozole is stopped.
Why is it called a 'suicide' inhibitor?
Exemestane resembles the natural substrate of aromatase. The enzyme processes it into an intermediate that binds covalently to the active site, permanently disabling that enzyme molecule — so it 'destroys' the enzyme it acts on.
Does exemestane affect bone density?
In clinical studies, exemestane use was associated with reductions in bone mineral density over time. Bone health is a commonly monitored consideration during extended use.
References
Related compounds
Aromatase inhibitor (AI). Used to control estrogen levels during TRT. Brand name Arimidex.
A potent non-steroidal aromatase inhibitor that strongly suppresses estradiol. Used to manage estrogen on TRT/cycles and to treat gynecomastia; because it is very powerful, low or every-other-day dosing is common to avoid crashing estrogen.
A SERM that blocks estrogen at breast tissue, used by men to prevent or treat gynecomastia and as a post-cycle therapy agent to restore the HPG axis. Unlike aromatase inhibitors it does not lower systemic estradiol.